Table 1.
Characteristics of included studies
| Study characteristics | All studies (n = 133) | Randomized studies (n = 29) | Non-randomized studies (n = 104) | P |
|---|---|---|---|---|
| Study drug, n (%) | ||||
| hydroxychloroquine+azithromycin | 27 (20) | 4 (14) | 23 (22) | 0.43 |
| hydroxychloroquine | 22 (17) | 7 (24) | 15 (14) | 0.26 |
| IL-6 inhibitors | 36 (27) | 3 (10) | 33 (32) | 0.03 |
| corticosteroids | 26 (20) | 6 (21) | 20 (19) | 0.80 |
| convalescent plasma | 10 (8) | 3 (10) | 7 (7) | 0.45 |
| remdesivir | 5 (4) | 3 (10) | 2 (2) | 0.07 |
| othera | 7 (5) | 3 (10) | 4 (4) | 0.17 |
| IF, median (IQR) | 4.8 (3.3–14.8) | 45.5 (17.1–64.0) | 4.3 (3.2–7.2) | <0.001 |
| Multicentred, n (%) | 61 (46) | 20 (69) | 41 (39) | 0.006 |
| Sample size, median (IQR) | 199 (83–513) | 243 (111–464) | 191 (80–550) | <0.001 |
| Clinical severity, n (%) | ||||
| mild | 5 (4) | 2 (7) | 3 (3) | 0.30 |
| moderate | 29 (22) | 7 (24) | 22 (21) | 0.80 |
| severe | 78 (59) | 16 (55) | 62 (60) | 0.68 |
| critical | 21 (16) | 4 (14) | 17 (16) | >0.999 |
| Age (years), median (IQR) | 62 (51.5–71) | 58.7 (47.6–68.6) | 63 (52.5–72.9) | 0.31 |
| Percentage male, median (IQR) | 62 (56.7–69.5) | 61.1 (58.3–66) | 62 (56.3–70.5) | 0.07 |
| Primary endpoint overall survival, n (%) | 43 (32) | 3 (10) | 40 (38) | 0.003 |
| Overall survival measurement timeframe (days), median (IQR) | 28 (21–30) | 28 (21–28) | 28 (21–30) | 0.36 |
| Industry sponsorship, n (%) | 9 (7) | 6 (21) | 3 (3) | 0.003 |
a
Including five antiretroviral drugs and two anti-influenza drugs.